These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

366 related items for PubMed ID: 24284475

  • 21. [Hallucinogen-induced psychological disorders].
    Hermle L, Kovar KA, Hewer W, Ruchsow M.
    Fortschr Neurol Psychiatr; 2008 Jun; 76(6):334-42. PubMed ID: 18512184
    [Abstract] [Full Text] [Related]

  • 22. Comparison of psychedelic and near-death or other non-ordinary experiences in changing attitudes about death and dying.
    Sweeney MM, Nayak S, Hurwitz ES, Mitchell LN, Swift TC, Griffiths RR.
    PLoS One; 2022 Jun; 17(8):e0271926. PubMed ID: 36001643
    [Abstract] [Full Text] [Related]

  • 23. Methoxetamine: An early report on the motivations for use, effect profile and prevalence of use in a UK clubbing sample.
    Winstock AR, Lawn W, Deluca P, Borschmann R.
    Drug Alcohol Rev; 2016 Mar; 35(2):212-7. PubMed ID: 25867295
    [Abstract] [Full Text] [Related]

  • 24. A survey of hallucinogenic mushroom use, factors related to usage, and perceptions of use among college students.
    Hallock RM, Dean A, Knecht ZA, Spencer J, Taverna EC.
    Drug Alcohol Depend; 2013 Jun 01; 130(1-3):245-8. PubMed ID: 23265089
    [Abstract] [Full Text] [Related]

  • 25. Shifting characteristics of ecstasy users ages 12-34 in the United States, 2007-2014.
    Palamar JJ, Mauro PM, Han BH, Martins SS.
    Drug Alcohol Depend; 2017 Dec 01; 181():20-24. PubMed ID: 29028555
    [Abstract] [Full Text] [Related]

  • 26. The pharmacology of psilocybin.
    Passie T, Seifert J, Schneider U, Emrich HM.
    Addict Biol; 2002 Oct 01; 7(4):357-64. PubMed ID: 14578010
    [Abstract] [Full Text] [Related]

  • 27. Metabolism and urinary disposition of N,N-dimethyltryptamine after oral and smoked administration: a comparative study.
    Riba J, McIlhenny EH, Bouso JC, Barker SA.
    Drug Test Anal; 2015 May 01; 7(5):401-6. PubMed ID: 25069786
    [Abstract] [Full Text] [Related]

  • 28. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
    Dos Santos RG, Bouso JC, Alcázar-Córcoles MÁ, Hallak JEC.
    Expert Rev Clin Pharmacol; 2018 Sep 01; 11(9):889-902. PubMed ID: 30102078
    [Abstract] [Full Text] [Related]

  • 29. The hallucinogenic world of tryptamines: an updated review.
    Araújo AM, Carvalho F, Bastos Mde L, Guedes de Pinho P, Carvalho M.
    Arch Toxicol; 2015 Aug 01; 89(8):1151-73. PubMed ID: 25877327
    [Abstract] [Full Text] [Related]

  • 30. Neuropharmacology of N,N-dimethyltryptamine.
    Carbonaro TM, Gatch MB.
    Brain Res Bull; 2016 Sep 01; 126(Pt 1):74-88. PubMed ID: 27126737
    [Abstract] [Full Text] [Related]

  • 31. The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption.
    Davis AK, Barsuglia JP, Lancelotta R, Grant RM, Renn E.
    J Psychopharmacol; 2018 Jul 01; 32(7):779-792. PubMed ID: 29708042
    [Abstract] [Full Text] [Related]

  • 32. Tolerance and limited cross-tolerance to the effects of N, N-dimethyltryptamine (DMT) and lysergic acid diethylamide-25 (LSD) on food-rewarded bar pressing in the rat.
    Kovacic B, Domino EF.
    J Pharmacol Exp Ther; 1976 Jun 01; 197(3):495-502. PubMed ID: 1064726
    [Abstract] [Full Text] [Related]

  • 33. Well-being, problematic alcohol consumption and acute subjective drug effects in past-year ayahuasca users: a large, international, self-selecting online survey.
    Lawn W, Hallak JE, Crippa JA, Dos Santos R, Porffy L, Barratt MJ, Ferris JA, Winstock AR, Morgan CJA.
    Sci Rep; 2017 Nov 09; 7(1):15201. PubMed ID: 29123145
    [Abstract] [Full Text] [Related]

  • 34. The hallucinogens and the inhalants.
    Cohen S.
    Psychiatr Clin North Am; 1984 Dec 09; 7(4):681-8. PubMed ID: 6097885
    [Abstract] [Full Text] [Related]

  • 35. United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.
    Barnett BS, Parker SE, Weleff J.
    Int J Drug Policy; 2022 Jan 09; 99():103473. PubMed ID: 34624734
    [Abstract] [Full Text] [Related]

  • 36. Plants and mushrooms of abuse.
    Spoerke DG, Hall AH.
    Emerg Med Clin North Am; 1990 Aug 09; 8(3):579-93. PubMed ID: 2201522
    [Abstract] [Full Text] [Related]

  • 37. The NBOMe hallucinogenic drug series: Patterns of use, characteristics of users and self-reported effects in a large international sample.
    Lawn W, Barratt M, Williams M, Horne A, Winstock A.
    J Psychopharmacol; 2014 Aug 09; 28(8):780-8. PubMed ID: 24569095
    [Abstract] [Full Text] [Related]

  • 38. [Consumption of psilocybin-containing hallucinogenic mushrooms by young people].
    Lassen JF, Lassen NF, Skov J.
    Ugeskr Laeger; 1992 Sep 21; 154(39):2678-81. PubMed ID: 1413197
    [Abstract] [Full Text] [Related]

  • 39. N,N-Dimethyltryptamine-Induced Psychosis.
    Paterson NE, Darby WC, Sandhu PS.
    Clin Neuropharmacol; 2015 Sep 21; 38(4):141-3. PubMed ID: 26166234
    [Abstract] [Full Text] [Related]

  • 40. Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.
    Rosenbaum D, Weissman C, Anderson T, Petranker R, Dinh-Williams LA, Hui K, Hapke E.
    J Psychopharmacol; 2020 Jun 21; 34(6):612-622. PubMed ID: 32108529
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.